Forskolin Derivative Composition for Oral Dual-Cytokine Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psoriasis treatments, particularly those targeting TNF-α and IL-17A, often rely on macromolecular drugs like antibodies that are costly, immunogenic, and unsuitable for oral administration, and small molecule drugs face challenges in development and efficacy, while existing small molecule immunosuppressants have insufficient efficacy and side effects.
Innovation Solution
Development of forskolin derivatives, specifically 6-(4-aminobutyryl)forskolin, 6-[4-(dimethylamino)butyryl]forskolin, 6-[3-aminopropionyl]forskolin, and 6-[3-(dimethylamino)propionyl]forskolin, which inhibit both TNF-α and IL-17A, combined with prostaglandin E2 or hydrocortisone, to achieve synergistic immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If macromolecular drugs like antibodies are used to target TNF-α and IL-17A, then therapeutic efficacy is improved, but cost increases and immunogenicity occurs
Solution Approach 1:
The patent creates small molecule copies that mimic the therapeutic effect of large antibody molecules. Instead of using actual antibodies (macromolecular drugs), the invention synthesizes smaller molecular compounds that replicate the immunosuppressive function by targeting the same inflammatory pathways, thereby avoiding immunogenicity while maintaining efficacy
Solution Approach 2:
The patent employs small molecule compounds that are cheaper to produce and manufacture compared to expensive antibody-based biologics. These small molecules can be synthesized through conventional chemical processes, making them more cost-effective and accessible while providing comparable therapeutic benefits for psoriasis treatment
2Reliability
If macromolecular drugs like antibodies are used, then therapeutic efficacy is improved, but ease of administration deteriorates due to injection requirement
Solution Approach 1:
The invention replaces injectable antibody molecules with orally available small molecule compounds. These small molecules can be administered through conventional oral routes, eliminating the need for injections while maintaining the ability to inhibit TNF-α and IL-17A signaling pathways effectively
Solution Approach 2:
The patent substitutes the mechanical injection process with simple oral administration. Instead of requiring syringes, needles, and injection procedures, the therapeutic agents are delivered through oral intake, significantly improving patient compliance and ease of use
3Ease of operation
If small molecule immunosuppressants are used, then ease of administration is improved, but efficacy deteriorates
Solution Approach 1:
The patent modifies the chemical parameters and structure of small molecule compounds to enhance their immunosuppressive potency. By optimizing molecular structure, concentration, and pharmacokinetic properties, the small molecules achieve efficacy levels comparable to biologics while maintaining the advantages of oral administration and lower cost
Solution Approach 2:
The invention uses composite small molecule formulations that combine multiple active components or use derivative structures to amplify therapeutic effect. These composite approaches allow the small molecules to achieve superior immunosuppressive efficacy by targeting multiple pathways or enhancing binding affinity to key inflammatory targets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The forskolin derivatives effectively reduce TNF-α and IL-17A secretion by up to 90% and 97%, respectively, demonstrating efficacy comparable to first-line clinical drugs with fewer side effects in psoriasis models, offering a new class of small molecule immunosuppressants.
Implementation Method 1
Forskolin is a compound extracted from the roots of Coleus forskohlii... It acts as an adenylate cyclase activator... The present invention concerns a pharmaceutical composition including a forskolin derivative... which inhibit both TNF-α and IL-17A
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided are a drug, a pharmaceutical composition, or a pharmaceutical kit for immunosuppression, for the treatment of conditions such as psoriasis, comprising a forskolin derivative or a salt thereof and optionally a prostaglandin compound or a glucocorticoid compound. Further provided is a method for immunosuppression, comprising administration of a forskolin derivative or a salt thereof and optionally a prostaglandin compound or a glucocorticoid compound. Forskolin derivatives show promise as a class of small-molecule drugs for achieving immunosuppression using new mechanisms, for the treatment of conditions such as psoriasis, when used alone or in combination with other substances. Compared with first-line antibody drugs, forskolin derivatives have significant advantages in process and price, and have comparable efficacy and fewer side effects compared with the first-line drug calcipotriol betamethasone ointment.